Literature DB >> 31296072

Factors Associated with Multidisciplinary Consultations in Patients with Early Stage Breast Cancer.

Farah F Quyyumi1,2, Jason D Wright2,3, Melissa K Accordino1,2, Donna Buono4, Cynthia W Law4, Grace C Hillyer2,4, Alfred I Neugut1,2,4, Dawn L Hershman1,2,4.   

Abstract

Purpose: Multidisciplinary care (MDC) encourages multiple specialists to formulate a unified treatment plan. We sought to determine the frequency and predictors of MDC and assess the association between MDC and nationally-recognized quality metrics in patients with breast cancer.
Methods: We used the surveillance, epidemiology, and end results-medicare dataset to evaluate patients diagnosed with stages I-III breast cancer who underwent breast-conserving surgery between 2002 and 2011 with follow-up to 2012. We defined MDC as a visit claim from a surgeon, radiation oncologist and medical oncologist within 12 months of diagnosis. We used multivariable regression analysis to determine the association between demographic and clinical variables and MDC, and to assess the association between MDC and three nationally-recognized quality indicators (adjuvant hormone therapy for hormone receptor-positive tumors, chemotherapy for hormone receptor-negative cancer, and radiation after lumpectomy).
Results: Of the 61,039 patients in our initial cohort, 53,849 (88.2%) saw a medical oncologist, 46,521 (76.2%) saw a radiation oncologist, and 43,280 (70.9%) were evaluated by all three providers the first year after diagnosis. MDC use was higher in patients with the highest socioeconomic status compared with the lowest [odds ratio (OR) 1.74, 95% CI 1.63-1.86], in patients diagnosed in later years, and those with stage III disease compared to stage I [OR 1.29, 95% CI 1.19-1.41]. Patients older in age (≥80 vs. 65-69 years, OR 0.33, 95% CI 0.31-0.34), patients with more comorbidities, those who lived in a rural setting compared to urban (OR 0.61, 95% CI 0.57-0.64), and unmarried patients (OR 0.79, 95% CI 0.76-0.82) were less likely to see all three providers. In a multivariable analysis, MDC use was associated with increased likelihood of meeting each quality metric.
Conclusion: Early stage breast cancer patients were evaluated by a surgeon, radiation oncologist and medical oncologist less than 75% of the time. Enhanced coordination of care and navigation programs may improve the quality of care delivered.

Entities:  

Keywords:  Breast cancer; SEER-Medicare; multidisciplinary care; quality indicators

Mesh:

Year:  2019        PMID: 31296072     DOI: 10.1080/07357907.2019.1624766

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  4 in total

1.  Survival Impact and Cost-Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub-Saharan Africa.

Authors:  Mariana Brandão; Assucena Guisseve; Carla Carrilho; Nuno Lunet; Genoveva Bata; João Firmino-Machado; Matos Alberto; Josefo Ferro; Carlos Garcia; Clésio Zaqueu; Astrilde Jamisse; Cesaltina Lorenzoni; Martine Piccart-Gebhart; Dina Leitão; Jotamo Come; Otília Soares; Alberto Gudo-Morais; Fernando Schmitt; Satish Tulsidás
Journal:  Oncologist       Date:  2021-01-06

2.  Factors influencing psychological distress and effects of stepwise psychological care on quality of life in patients undergoing chemotherapy after breast cancer surgery.

Authors:  Congmei Tu; Yongping He; Xue Ma
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study.

Authors:  Monica Tang; Andrea L Schaffer; Belinda E Kiely; Benjamin Daniels; Chee K Lee; Robert J Simes; Sallie-Anne Pearson
Journal:  Breast Cancer Res Treat       Date:  2021-02-22       Impact factor: 4.872

4.  Cancer prevention, risk reduction, and control: opportunities for the next decade of health care delivery research.

Authors:  Denalee M O'Malley; Catherine M Alfano; Michelle Doose; Anita Y Kinney; Simon J Craddock Lee; Larissa Nekhlyudov; Paul Duberstein; Shawna V Hudson
Journal:  Transl Behav Med       Date:  2021-11-30       Impact factor: 3.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.